15. The composition of any one of claims 1 to 13, wherein the compounds in said composition are formulated separately.

16. The composition for use of any one of claims 10 to 13, wherein the compounds in said composition are administered together, separately or sequentially.

17. The composition for use of any one of claims 10 to 13, wherein said composition is administered repeatedly to the subject.

18. The composition of any one of the preceding claims, wherein the ratio acamprosate/baclofen (w/w) is comprised between 0.05 and 1000.

19. The composition of any one of the preceding claims, wherein the dose of baclofen is less than 100 mg/day.

20. The composition of any one of the preceding claims, wherein the dose of acamprosate is less than 100 mg/day.

21. The composition of any one of the preceding claims, wherein said composition comprises a calcium salt of acamprosate.

22. ~~A method of treating a neurological disorder in a subject in need thereof, the method comprising administering to said subject an effective amount~~Use of a composition of any one of claims 1 to 9, 14, 15 or 18 to 21 in the manufacture of a medicament for the treatment of a neurological disorder.

23. The ~~method~~use of claim 22, wherein the neurological disorder is selected from Alzheimer's disease, an Alzheimer's disease related disorder, frontotemporal dementia, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, spinal cord injury, a peripheral neuropathy, alcoholism or alcohol withdrawal, traumatic brain injury or a brain ischemic event, Parkinson's disease, Lewy body dementia, Huntington's disease, a neurological manifestation of drug abuse, and drug abuse withdrawal.

24. Use of a composition of any one of claims 1 to 9, 14, 15 or 18-21, in the manufacture of a medicament for the treatment of a neurological disorder selected from Alzheimer's disease, an Alzheimer's disease related disorder, frontotemporal dementia, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, spinal cord